Efficacy of Dotarem (Gd-DOTA) Versus Magnevist (Gd-DTPA) for Late Gadolinium Enhancement Cardiac Magnetic Resonance and Relationship to Outcomes: A Pilot Study
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
Price : $35 *
At a glance
- Drugs Gadobutrol (Primary) ; Gadoterate-meglumine (Primary)
- Indications Coronary artery disease
- Focus Diagnostic use
- 17 Jan 2019 Planned End Date changed from 30 Sep 2018 to 30 Jun 2021.
- 17 Jan 2019 Planned primary completion date changed from 30 Sep 2018 to 31 Dec 2020.
- 22 Feb 2017 New trial record